查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1971169

CAR-T细胞疗法市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终使用者、流程、阶段、解决方案划分

CAR T Cell Therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 300 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计CAR-T细胞疗法市场将从2024年的60亿美元成长到2034年的218亿美元，复合年增长率约为13.8%。 CAR-T细胞疗法市场涵盖嵌合体抗原受体T细胞疗法的研发和商业化，该疗法旨在靶向并摧毁癌细胞。该市场的特点是基因工程和个人化医疗领域的尖端进展。随着癌症患者数量的增加和对创新治疗方法需求的成长，提高疗效、安全性和可近性成为推动市场成长的关键因素。主要趋势包括生物技术公司与学术机构的合作、监管政策的发展以及全球临床试验的扩展。

CAR-T细胞疗法市场正经历强劲成长，这主要得益于免疫疗法和个人化医疗的进步。骨髓恶性肿瘤领域主导市场，其中针对白血病和淋巴瘤等B细胞恶性肿瘤的疗法在疗效和普及率方面领先。固态肿瘤领域是第二大成长领域，在针对特定抗原方面取得了令人瞩目的进展。在血液系统恶性肿瘤领域，CD19标靶治疗特别突出，这主要得益于其在治疗某些白血病和淋巴瘤方面的成功。 BCMA标靶治疗领域也正在迅速发展，这反映了在对抗多发性骨髓瘤方面取得的显着进展。在固态肿瘤领域，针对HER2和EGFR等抗原的治疗方法进展显着，并有望带来突破性进展。正在进行的研究和临床试验正在扩大治疗方法选择，并凸显创新方法在克服治疗抗药性方面的重要性。投资于生产能力和监管途径对于扩大这些疗法的规模、确保更广泛的可及性和可负担性至关重要。

市场区隔
类型 自体CAR-T细胞疗法、异体CAR-T细胞疗法
产品 Yeskata、Kymriah、Tekartas、Bryanji、Abekuma
服务 研发、生产製造、品管、法规遵循、临床试验、物流、咨询
科技 基因编辑、慢病毒载体、CRISPR、睡美人转座子
适应症 骨髓恶性肿瘤、固态肿瘤、非何杰金氏淋巴瘤、急性淋巴性白血病、多发性骨髓瘤、慢性淋巴性白血病
最终用户 医院、癌症治疗中心、研究机构、生技公司、製药公司
过程 细胞采集、细胞工程、细胞增生、品质检测、冷冻保存
步 临床前研究、临床试验与商业化
解决方案 病患监测、资料管理、供应链管理

市场概况：

CAR-T细胞疗法市场正经历动态变化，市场份额、定价策略和产品发布方面均取得了显着进展。丰富的创新治疗方法研发管线和对具有竞争力的定价策略的策略性关注是该市场的关键特征。主要企业正在推出新型治疗方法并强化其产品组合，以占据更大的市场份额。此外，联盟和伙伴关係正在增强竞争优势并推动市场成长。在竞争方面，该市场的特征是主要製药公司之间的激烈竞争。基准分析显示，各公司正在利用先进技术来保持其竞争优势。法规结构，尤其是在北美和欧洲，对塑造市场动态至关重要。这些法规确保了药物的安全性和有效性，并影响企业的市场准入和扩大策略。在技​​术进步、癌症发病率上升以及对个人化医疗日益增长的需求的推动下，该市场蓄势待发，即将迎来成长。儘管高昂的治疗成本和监管障碍等挑战依然存在，但创新潜力依然巨大。

主要趋势和驱动因素：

CAR-T细胞疗法市场正经历强劲成长，这主要得益于基因工程和免疫疗法的进步。关键趋势包括开发具有更高特异性和更低毒性的新一代CAR-T细胞。生产流程的创新降低了成本，使更多患者能够获得治疗。此外，监管支持和加速核准计划正在加速新型治疗方法的市场推广。癌症和骨髓恶性肿瘤发生率的上升是关键驱动因素，增加了对有效治疗方法的需求。生物技术公司和研究机构之间的合作正在促进创新，并推动新型CAR-T细胞产品的开发。 CAR-T细胞疗法在肿瘤治疗领域之外的适应症拓展以及在自体免疫感染疾病的应用都蕴藏着巨大的潜力。预计对研发投入的增加将带来变革性治疗方法，从而推动CAR-T细胞疗法市场持续成长，并显着改善患者照护。

限制与挑战：

CAR-T细胞疗法市场面临许多重大限制和挑战。其中一个关键挑战是CAR-T细胞疗法的高昂费用，这限制了许多患者的治疗机会。高成本源自于复杂的生产过程和个人化的治疗方案。监管障碍也构成重大障碍，要求治疗方法必须经过严格的测试和核准程序，从而延长了上市时间。此外，能够管理和管理这些先进治疗方法的专业人员短缺也限制市场发展。这种短缺影响了CAR-T细胞疗法的扩充性和广泛普及。此外，还存在严重副作用的风险，例如细胞激素释放综合征，这可能会让患者和医疗服务提供者望而却步。最后，供应链中的物流挑战，例如对精确温度控制和及时交付的需求，也使CAR-T细胞疗法的分销变得复杂。所有这些因素共同阻碍了市场成长和普及。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 自体CAR-T细胞疗法
    • 同种异体CAR-T细胞疗法
  • 市场规模及预测：依产品划分
    • 耶斯卡塔
    • 凯姆里亚
    • Tekartas
    • 布里安吉
    • 阿别隈
  • 市场规模及预测：依服务划分
    • 研究与开发
    • 製造业
    • 品管
    • 监理合规
    • 临床试验
    • 后勤
    • 咨询
  • 市场规模及预测：依技术划分
    • 基因编辑
    • 慢病毒载体
    • CRISPR
    • 睡美人转座子
  • 市场规模及预测：依应用领域划分
    • 骨髓恶性肿瘤
    • 固体癌
    • 非何杰金氏淋巴瘤
    • 急性淋巴性白血病
    • 多发性骨髓瘤
    • 慢性淋巴性白血病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症治疗中心
    • 研究所
    • 生技公司
    • 製药公司
  • 市场规模及预测：依製程划分
    • 细胞收集
    • 细胞工程
    • 细胞增殖
    • 品质检测
    • 冷冻保存
  • 市场规模及预测：依阶段划分
    • 临床前阶段
    • 临床试验
    • 商业化
  • 市场规模及预测：按解决方案划分
    • 病患监测
    • 资料管理
    • 供应链管理

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Legend Biotech
  • Autolus Therapeutics
  • Cellectis
  • Poseida Therapeutics
  • Tessa Therapeutics
  • Adaptimmune Therapeutics
  • Kite Pharma
  • Allogene Therapeutics
  • Caribou Biosciences
  • Cabaletta Bio
  • Immatics
  • Atara Biotherapeutics
  • Genocea Biosciences
  • Sorrento Therapeutics
  • Precision BioSciences

第九章：关于我们

简介目录
Product Code: GIS33699

CAR T Cell Therapy Market is anticipated to expand from $6 billion in 2024 to $21.8 billion by 2034, growing at a CAGR of approximately 13.8%. The CAR T Cell Therapy Market encompasses the development and commercialization of chimeric antigen receptor T-cell therapies, which are engineered to target and destroy cancer cells. This market is characterized by cutting-edge advancements in genetic engineering and personalized medicine. The increasing prevalence of cancer and the demand for innovative treatments are propelling growth, with a focus on improving efficacy, safety, and accessibility. Key trends include collaborations between biotech firms and academic institutions, regulatory advancements, and the expansion of clinical trials globally.

The CAR T Cell Therapy Market is experiencing robust growth, propelled by advancements in immunotherapy and personalized medicine. The segment focusing on hematological malignancies dominates, with therapies targeting B-cell malignancies such as leukemia and lymphoma leading in efficacy and adoption. Solid tumors represent the second highest performing segment, showcasing promising developments in targeting specific antigens. Within the hematological segment, the sub-segment of CD19-targeted therapies is particularly prominent, driven by their success in treating certain leukemias and lymphomas. The sub-segment addressing BCMA-targeted therapies is gaining momentum, reflecting significant strides in combating multiple myeloma. In the solid tumor segment, advancements in targeting antigens like HER2 and EGFR are notable, offering potential breakthroughs. Ongoing research and clinical trials are expanding the therapeutic landscape, underscoring the importance of innovative approaches in overcoming treatment resistance. Investment in manufacturing capabilities and regulatory pathways is crucial to scaling these therapies, ensuring broader access and affordability.

Market Segmentation
TypeAutologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy
ProductYescarta, Kymriah, Tecartus, Breyanzi, Abecma
ServicesResearch and Development, Manufacturing, Quality Control, Regulatory Compliance, Clinical Trials, Logistics, Consulting
TechnologyGene Editing, Lentiviral Vectors, CRISPR, Sleeping Beauty Transposon
ApplicationHematologic Malignancies, Solid Tumors, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
End UserHospitals, Cancer Treatment Centers, Research Institutes, Biotechnology Companies, Pharmaceutical Companies
ProcessCell Collection, Cell Engineering, Cell Expansion, Quality Testing, Cryopreservation
StagePreclinical, Clinical Trials, Commercialization
SolutionsPatient Monitoring, Data Management, Supply Chain Management

Market Snapshot:

The CAR T Cell Therapy market is witnessing a dynamic shift with significant advancements in market share, pricing strategies, and product launches. The market is characterized by a robust pipeline of innovative therapies and a strategic focus on competitive pricing. Key players are introducing novel treatments, enhancing their portfolios to capture larger market segments. The landscape is further enriched by collaborations and partnerships, fostering a competitive edge and driving growth. In terms of competition, the market is marked by intense rivalry among leading pharmaceutical companies. Benchmarking reveals that companies are leveraging advanced technologies to maintain competitive advantages. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics. These regulations ensure safety and efficacy, influencing market entry and expansion strategies. The market is poised for growth, driven by technological advancements, increasing prevalence of cancer, and rising demand for personalized medicine. Challenges such as high treatment costs and regulatory hurdles persist, yet the potential for innovation remains substantial.

Geographical Overview:

The CAR T Cell Therapy market is witnessing notable expansion across various regions, each demonstrating unique growth dynamics. North America remains at the forefront, propelled by pioneering research and substantial investments in biotechnology. The presence of leading pharmaceutical companies and advanced healthcare infrastructure further bolsters the market. Europe follows, with robust research initiatives and favorable regulatory frameworks fostering innovation in CAR T Cell Therapy. The region's commitment to personalized medicine enhances its market position. In Asia Pacific, the market is burgeoning, driven by increased healthcare spending and technological advancements. Countries like China and Japan are emerging as key players, investing heavily in research and development. Latin America and the Middle East & Africa are increasingly recognizing the potential of CAR T Cell Therapy. In Latin America, growing healthcare awareness and infrastructure improvements are driving market growth. Meanwhile, the Middle East & Africa are focusing on strategic collaborations to enhance their capabilities in this transformative therapy.

Key Trends and Drivers:

The CAR T Cell Therapy Market is experiencing robust growth fueled by advancements in genetic engineering and immunotherapy. Key trends include the development of next-generation CAR T cells, which are designed to enhance specificity and reduce toxicity. Innovations in manufacturing processes are driving down costs, making therapies more accessible to a broader patient base. Furthermore, regulatory support and fast-track approvals are accelerating the introduction of new therapies into the market. The rising prevalence of cancer and hematological malignancies is a significant driver, increasing demand for effective treatment options. Collaborations between biotech companies and research institutions are fostering innovation, leading to the development of novel CAR T cell products. Opportunities are abundant in expanding the therapeutic indications beyond oncology, exploring applications in autoimmune diseases and infectious diseases. The growing investments in research and development are expected to yield transformative therapies, positioning the CAR T Cell Therapy Market for sustained growth and substantial advancements in patient care.

Restraints and Challenges:

The CAR T Cell Therapy Market faces several significant restraints and challenges. A primary challenge is the exorbitant cost associated with CAR T cell therapies, which limits accessibility for many patients. This high cost stems from complex manufacturing processes and personalized treatment regimens. Regulatory hurdles also pose a significant barrier, as therapies must undergo rigorous testing and approval procedures, prolonging time to market. Moreover, the market is constrained by a lack of skilled professionals who can administer and manage these advanced therapies. This shortage impacts the scalability and widespread adoption of CAR T cell treatments. Additionally, there is a risk of severe side effects, including cytokine release syndrome, which can deter patients and healthcare providers. Finally, logistical challenges in the supply chain, such as the need for precise temperature control and timely delivery, complicate the distribution of CAR T cell therapies. These factors collectively impede market growth and accessibility.

Key Players:

Legend Biotech, Autolus Therapeutics, Cellectis, Poseida Therapeutics, Tessa Therapeutics, Adaptimmune Therapeutics, Kite Pharma, Allogene Therapeutics, Caribou Biosciences, Cabaletta Bio, Immatics, Atara Biotherapeutics, Genocea Biosciences, Sorrento Therapeutics, Precision BioSciences

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Autologous CAR T Cell Therapy
    • 4.1.2 Allogeneic CAR T Cell Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Yescarta
    • 4.2.2 Kymriah
    • 4.2.3 Tecartus
    • 4.2.4 Breyanzi
    • 4.2.5 Abecma
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Research and Development
    • 4.3.2 Manufacturing
    • 4.3.3 Quality Control
    • 4.3.4 Regulatory Compliance
    • 4.3.5 Clinical Trials
    • 4.3.6 Logistics
    • 4.3.7 Consulting
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Editing
    • 4.4.2 Lentiviral Vectors
    • 4.4.3 CRISPR
    • 4.4.4 Sleeping Beauty Transposon
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hematologic Malignancies
    • 4.5.2 Solid Tumors
    • 4.5.3 Non-Hodgkin Lymphoma
    • 4.5.4 Acute Lymphoblastic Leukemia
    • 4.5.5 Multiple Myeloma
    • 4.5.6 Chronic Lymphocytic Leukemia
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Treatment Centers
    • 4.6.3 Research Institutes
    • 4.6.4 Biotechnology Companies
    • 4.6.5 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Cell Collection
    • 4.7.2 Cell Engineering
    • 4.7.3 Cell Expansion
    • 4.7.4 Quality Testing
    • 4.7.5 Cryopreservation
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Patient Monitoring
    • 4.9.2 Data Management
    • 4.9.3 Supply Chain Management

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Legend Biotech
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Autolus Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cellectis
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Poseida Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Tessa Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Adaptimmune Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Kite Pharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Allogene Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Caribou Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cabaletta Bio
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immatics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Atara Biotherapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Genocea Biosciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sorrento Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Precision BioSciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us